Other articles

ESC 2019 | EVOPACS: Evolocumab para reducir el colesterol en síndromes coronarios agudos

ESC 2019 | EVOPACS: Evolocumab to Reduce Cholesterol in Acute Coronary Syndromes

ESC 2019 | EVOPACS: Evolocumab to Reduce Cholesterol in Acute Coronary Syndromes

Eight weeks of treatment with evolocumab added to a regimen of high-intensity statins in patients with acute coronary syndrome reduced significantly LDL cholesterol levels and was safe, compared with statins + placebo, according to the EVOPACS study presented last Saturday at the European Society of Cardiology (ESC) Congress 2019 Scientific Sessions in Paris and simultaneously

ESC 2019 | HOPE 4: derribar barreras para tratar factores de riesgo en países en desarrollo

ESC 2019 | HOPE 4: Overcoming Obstacles to Treat Risk Factors in Developing Countries

Exhaustive intervention carried out by healthcare non-medical healthcare professionals with the support of community members resulted in a significant reduction of systolic blood pressure, LDL cholesterol levels and CAD risk in patients of Malaysia and Colombia, according to this study presented at ESC 2019 in Paris and simultaneously published in Lancet. This intervention translated into

ESC 2019 | DAPA-HF: Dapagliflozina muestra beneficios en todos los subgrupos

ESC 2019 | DAPA-HF: Dapagliflozin Shows Benefit for All Subgroups

Dapagliflozin (a sodium glucose co-transporter 2 [SGLT2] inhibitor), when indicated concomitantly with standard therapy, reduces significantly the risk of worsening heart failure events and cardiovascular events, and improves symptoms in patients with heart failure and reduced ejection fraction according to this new work presented during last Sunday’s scientific sessions at the European Society of Cardiology

ESC 2019 | PARAGON-HF: Sacubitril/Valsartan Somewhat Disappointing, though a Few Would Benefit.

The combination Sacubitril/valsartan did not reduce the risk of rehospitalization for heart failure or cardiovascular death in patients with cardiac failure symptoms and preserved ejection fraction, according to the new study presented on Sunday at ESC 2019 scientific session in Paris and simultaneously published in NEJM. Despite the negative results, we remain hopeful that this


Must Post MI Patients Use B Blockers for Life?

Long-term use of B blockers after myocardial infarction has been questioned for a while now; in fact, admittedly, beyond the three year follow up its benefits remain unclear. It is particularly controversial in elderly patients and this recent study published in Circ Cardiovasc Qual Outcomes sheds some light on the matter. The study followed 6893

Efectos de la radiación cerebral en Cardiólogos Intervencionistas

Heart and Brain: Risk Factors, Atrial Fibrillation and Dementia

For decades, physiologists have known what cardiologists often forget: heart and brain communicate intensely in a healthy person, and in a wide range of cardiovascular diseases they could damage one another. Multiple actions and immediate reactions in the brain adequately adapt heart function to bodily needs, such as anxiety and frustration, which might impair adequate

Oportunidades perdidas en pacientes con enfermedad vascular periférica

Though Systolic BP Seems More Important, Diastolic BP Should Not Be Disregarded

Systolic hypertension is more often associated to cardiovascular events. However, diastolic blood pressure should not be disregarded, since it can also predict even worse outcomes. Although systolic blood pressure is very frequently associated to adverse cardiovascular events, by no means should diastolic blood pressure be considered unimportant. Such is the message of this study recently

Nuevas alternativas prometedoras para la insuficiencia mitral

Dietary Supplements and Diets Show No Impact on Cardiovascular Risk

Americans spend billions in dietary supplements every year but, in truth, this money is only wasted, according to evidence form a recent study published in Intern Med. Most of dietary interventions and nutritional supplements including multi-vitamins, selenium and antioxidants, do not reduce cardiovascular risk or mortality, according to this large analysis and systematic revision of

Las nuevas guías Europeas de Hipertensión contrastan con las Americanas

Many Guidelines, Much Confusion. Blood Pressure Targets in the Elderly

Seeing as hypertension prevalence and incidence increases with age, treating elderly patients of paramount importance. The AHA/ACC guidelines have lowered cohort hypertension thresholds to >130/80 mmHg, whereas the European guidelines have kept the classic >140/90 mmHg, though recommending lower thresholds for most patients at the same time. Lower than 130/80 mmHg is recommended with the

¿Se justifica utilizar filtro de protección distal en los puentes venosos?

After Much Toing and Froing, Gastrointestinal Protection Is Back to the Forefront

Several clinical guidelines differ in their recommendation regarding the prescription of proton pump inhibitors to patients being treated with dual antiplatelet therapy after infarction. In 2015, the European Society of Cardiology (ESC) recommended their use in patients with high bleeding risk; however, in the 2017 update that recommendation became general after the assumption that, for

EuroPCR 2019 | Global Leaders: La monoterapia con ticagrelor a largo plazo podría tener un lugar en angioplastias complejas.

EuroPCR 2019 | Global Leaders: Ticagrelor Monotherapy at Long Term Could Have a Role in Complex PCI

This post hoc analysis of what had been a trial with negative outcomes should be considered only as a hypothesis generator. Patients receiving complex PCI treated with ticagrelor monotherapy after one-month dual antiaggregation therapy (DAPT) showed better results at 2 years when compared against patients receiving a conventional DAPT scheme. In the global analysis, this